|drug3010||SOC plus Placebo IV Wiki||1.00|
|drug3009||SOC plus 15mg/kg EB05 IV Wiki||1.00|
There is one clinical trial.
Coronavirus infection is responsible for muscle wasting (sarcopenia), especially during prolonged stays in intensive care. Sarcopenia, in its functional aspect also seems major in patients hospitalized for this infection, in non-ICU unit. Weight loss also appears to be significant, despite a prevalence of overweight and obesity in severe forms. Undernutrition in the obese patient is also possible (undernourished obese and sarcopenia obesity). Anosmia and dysgeusia participate in undernutrition by reducing energy intake. The rehabilitation of these patients requires nutritional support (increased protein intake) associated with progressive retraining to physical activity. An early and proactive management procedure within Coronavirus disease-19 units has been implemented in conjunction with the Transversal Nutrition Unit (TNU). This nutritional care must be continued after discharge. Follow-up by teleconsultation or telephone consultation is put in place after the patient's discharge Primary Objective: Evaluation of nutritional status at the time of admission and discharge and home follow-up in outgoing patients from Coronavirus disease-19 Units Secondary objectives: Description of the evolution of food intake, diversity of food and coverage of needs Evaluation of the muscular strength of the wrist (by grip test in hospital) and on the arms and legs after return home (visual analog scale) Evolution of anosmia and dysgeusia (at the time of hospital admission, at the time of hospital discharge and at home) Level of physical training before infection (IPAQ) Description of the general state of health measured by the performance index - world health organization scale Description of nutritional prescriptions Description of the prevention measures and incidence of Inappropriate Refeeding Syndrome (IRS) Care needs assessments
Description: weightMeasure: nutritional evaluation Time: before Covid, at hospital discharge and between 7 and 45 days after discharge
Description: BMIMeasure: nutritional evaluation Time: before Covid, at at the time of hospital admission, at the time of hospital discharge and between 7 and 45 days after discharge
Description: hand gripMeasure: muscle strenght Time: at the time of hospital admission and at the time of hospital discharge
Description: Caloric accountMeasure: food intake Time: at the time of hospital admission, at the time of hospital discharge
Description: self evaluation of food intakeMeasure: food intake Time: between 7 and 45 days after discharge
Description: self evaluation of muscle strenghtMeasure: muscle strenght Time: between 7 and 45 days after discharge
Description: albuminemia transthyretinemia electrolytes dosage inflammation statusMeasure: biological nutritional status Time: at the time of hospital admission, at the time of hospital discharge
Description: anosmia and agueusia evolutionMeasure: anosmia Time: at the time of hospital admission, at the time of hospital discharge and between 7 and 45 days after discharge
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports